{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:43:25Z","timestamp":1787496205522,"version":"build-2736575974"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:p>Background\u2003Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by an increased risk of thrombotic complications due to a persistent pro-thrombotic and inflammatory state. Atrial fibrillation (AF) is a common cardiac arrhythmia and an established risk factor for thromboembolism; however, its impact on thrombotic complications in patients with MPN remains incompletely characterized.<\/jats:p>\n                  <jats:p>Material and Methods\u2003This multicenter, real-world retrospective study analyzed 2,683 MPN patients diagnosed between 1976 and 2024 to investigate the impact of AF on thrombotic events, bleeding risk, and survival outcomes.<\/jats:p>\n                  <jats:p>Results\u2003Patients with MPN and AF (MPN-AF) had a higher rate of thrombotic events, with arterial thrombosis predominating (67% vs. 43%, p &lt; 0.0001). Despite this arterial phenotype, 36.7% of MPN-AF patients did not receive antiplatelet therapy. Thrombosis rates remained high in AF patients despite cytoreductive therapy. Kaplan\u2013Meier analysis revealed that AF was linked to significantly shorter overall survival (181 months vs. 265 months, HR: 1.86, 95% CI: 1.53\u20132.26, p &lt; 0.0001), particularly in essential thrombocythemia and MF subtypes.<\/jats:p>\n                  <jats:p>Conclusion\u2003Our findings highlight that the thrombotic profile of MPN patients with AF differs from that observed in the general AF population, with a clear predominance of arterial events. Conventional AF management focused on anticoagulation may incompletely address the predominantly arterial thrombotic phenotype observed in MPN. The treatment patterns observed in our cohort\u2013with frequent reliance on anticoagulation alone and limited use of antiplatelet therapy\u2013suggest a need for more disease-adapted antithrombotic considerations in this subgroup. Prospective studies are needed to clarify the contribution of inflammatory and vascular mechanisms to thrombotic risk in MPN-AF.<\/jats:p>","DOI":"10.1055\/a-2869-7105","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:16:33Z","timestamp":1778714193000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Atrial Fibrillation on Thrombotic Complications in Myeloproliferative Neoplasms Real-World Analysis"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2550-8679","authenticated-orcid":false,"given":"Olga","family":"Demska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-7287","authenticated-orcid":false,"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9matologie Clinique, Institut de Canc\u00e9rologie et d'h\u00e9matologie, CHU de Brest, Brest-France"},{"name":"Department of Hematology and Clinical Hemostasis, Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-9452","authenticated-orcid":false,"given":"Marta","family":"Szandruk-Bender","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Pharmacology, Wroclaw Medical University, Wroc\u0142aw, Lower Silesian Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-8298","authenticated-orcid":false,"given":"Danijela","family":"Lekovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0478","authenticated-orcid":false,"given":"Weronika","family":"Lebowa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Lesser Poland Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-6595","authenticated-orcid":false,"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Lesser Poland Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-3587","authenticated-orcid":false,"given":"Aleksandra","family":"Go\u0142os","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, \u0141\u00f3d\u017a, \u0141\u00f3d\u017a Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-5017","authenticated-orcid":false,"given":"Patryk","family":"Sobieralski","sequence":"additional","affiliation":[{"name":"Medical University of Gda\u0144sk, Gda\u0144sk, Pomeranian Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Skarupski","sequence":"additional","affiliation":[{"name":"Faculty of Pure and Applied Mathematics, Wroc\u0142aw University of Science and Technology, Wroc\u0142aw, Lower Silesian Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Karasek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland"},{"name":"Cardio-Oncology Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Erdos","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-143X","authenticated-orcid":false,"given":"Joseph Michael","family":"Scandura","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-8668","authenticated-orcid":false,"given":"Marta","family":"Sobas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Bydgoszcz, Poland"},{"name":"Department of Hematology, Jan Biziel University Hospital No 2 in Bydgoszcz, Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"H C Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: what do we know?","volume":"9","author":"L A Anderson","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"A Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"H C Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-021-00566-5","article-title":"Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients","volume":"11","author":"J How","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9464","key":"ref7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"E J Baxter","year":"2005","journal-title":"Lancet"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"R L Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"P Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/europace\/euab180","article-title":"Atrial fibrillation and risk of venous thromboembolism: a Swedish Nationwide Registry Study","volume":"23","author":"B Hornestam","year":"2021","journal-title":"Europace"},{"issue":"36","key":"ref11","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"I C Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"13","key":"ref12","doi-asserted-by":"crossref","first-page":"e71015","DOI":"10.1002\/cam4.71015","article-title":"Incidence, outcomes and risk factors for atrial fibrillation in patients with JAK2V617F-positive myeloproliferative neoplasms","volume":"14","author":"G Teng","year":"2025","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1055\/a-2767-0451","article-title":"Atrial fibrillation in Philadelphia chromosome-negative myeloproliferative neoplasms: thromboinflammatory crosstalk with a focus on the nlrp3 inflammasome","author":"O Demska","year":"2025","journal-title":"Thromb Haemost"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"26","key":"ref15","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"T Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"T Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17474086.2023.2174515","article-title":"Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review","volume":"16","author":"M Baysal","year":"2023","journal-title":"Expert Rev Hematol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2869-7105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:16:43Z","timestamp":1778714203000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2869-7105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1055\/a-2869-7105","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}